- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Myeloblasts.
Displaying page 1 of 1.
EudraCT Number: 2015-000221-37 | Sponsor Protocol Number: Pevonedistat-2001 | Start Date*: 2016-02-22 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. (Takeda) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplasti... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Higher-risk myelodysplastic syndromes (MDS), Chronic myelomonocytic leukemia (CMML), Low-blast acute myelogenous leukemia (AML) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IE (Completed) BG (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001639-38 | Sponsor Protocol Number: MDS/2013 | Start Date*: 2016-12-06 |
Sponsor Name:1st Dep. of Medicine, General University Hospital (VFN) in Prague | ||
Full Title: Contribution to verify the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy 5 - Azacitidine patients with the high risk Myelodysplastic syndrome. | ||
Medical condition: Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000318-40 | Sponsor Protocol Number: Pevonedistat-3001 | Start Date*: 2018-04-25 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. (Takeda) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Higher-Risk Myelodysplastic Syndromes (MDS) Chronic Myelomonocytic Leukemia (CMML) Low-Blast Acute Myelogenous Leukemia (AML) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001075-37 | Sponsor Protocol Number: TUD-FHCRCD-010 | Start Date*: 2007-05-18 |
Sponsor Name:University of Technology Dresden | ||
Full Title: A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia. | ||
Medical condition: MDS and AML are predominantly diseases of older patients. For patients with advanced or chemotherapy refractory disease HCT is currently the only strategy that offers curative therapy. Unfortunat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003426-32 | Sponsor Protocol Number: DCOne-002 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:DCprime bv | |||||||||||||
Full Title: AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WIT... | |||||||||||||
Medical condition: The medical condition investigated are patients with acute myeloid leukemia in complete remission with persistent minimal residual disease and as such are at high risk of relapse. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) NO (Completed) SE (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004479-11 | Sponsor Protocol Number: CMBG453B12201 | Start Date*: 2019-05-30 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodys... | |||||||||||||
Medical condition: Adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) AT (Prematurely Ended) GR (Completed) HU (Completed) NO (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003421-28 | Sponsor Protocol Number: TUD-HINKL1-059 | Start Date*: 2014-07-10 | |||||||||||
Sponsor Name:Technische Universität Dreden | |||||||||||||
Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia | |||||||||||||
Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005493-10 | Sponsor Protocol Number: MB-106 | Start Date*: 2022-03-22 | |||||||||||
Sponsor Name:Moleculin Biotech, Inc. | |||||||||||||
Full Title: Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003810-38 | Sponsor Protocol Number: KCP-8602-801 | Start Date*: 2021-12-01 | |||||||||||||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
Full Title: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/R... | |||||||||||||||||||||||||||||||||
Medical condition: High-risk primary refractory MDS patients | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000705-25 | Sponsor Protocol Number: AT148002 | Start Date*: 2021-06-09 | |||||||||||
Sponsor Name:ALX Oncology Inc. | |||||||||||||
Full Title: A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) | |||||||||||||
Medical condition: Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002964-25 | Sponsor Protocol Number: GO40800 | Start Date*: 2019-04-25 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE IB/II STUDY, EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY A... | |||||||||||||
Medical condition: Acute myeloid leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004134-42 | Sponsor Protocol Number: SLSG18-301 | Start Date*: 2020-09-22 | |||||||||||
Sponsor Name:Sellas Life Sciences | |||||||||||||
Full Title: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid ... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Completed) IT (Trial now transitioned) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003386-28 | Sponsor Protocol Number: GH29914 | Start Date*: 2016-05-11 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase Ib/II multi-arm study with venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients ≥ 60 years with relapsed or refractory acute myeloid leukem... | |||||||||||||
Medical condition: Relapsed or Refractory Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000074-19 | Sponsor Protocol Number: GCP#03.01.020 | Start Date*: 2014-10-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | |||||||||||||||||||||||||||||||||
Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic... | |||||||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) IT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000704-28 | Sponsor Protocol Number: GCP#05.01.020 | Start Date*: 2016-06-16 | ||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord... | ||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
